{"id":"https://openalex.org/W46755809","doi":null,"title":"Efficacy of risperidone on positive features of schizophrenia.","display_name":"Efficacy of risperidone on positive features of schizophrenia.","publication_year":1994,"publication_date":"1994-05-01","ids":{"openalex":"https://openalex.org/W46755809","mag":"46755809","pmid":"https://pubmed.ncbi.nlm.nih.gov/7520904"},"language":"en","primary_location":{"id":"pmid:7520904","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7520904","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111582496","display_name":"Joseph P. McEvoy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J P McEvoy","raw_affiliation_strings":["Department of Psychiatry, Duke University Medical Center, Durham, N.C"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Duke University Medical Center, Durham, N.C","institution_ids":["https://openalex.org/I4210126298"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5111582496"],"corresponding_institution_ids":["https://openalex.org/I4210126298"],"apc_list":null,"apc_paid":null,"fwci":1.5804,"has_fulltext":false,"cited_by_count":39,"citation_normalized_percentile":{"value":0.81192072,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"55 Suppl","issue":null,"first_page":"18","last_page":"21"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12308","display_name":"Mental Health and Psychiatry","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1211","display_name":"Philosophy"},"field":{"id":"https://openalex.org/fields/12","display_name":"Arts and Humanities"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":1.0},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.7889999747276306},{"id":"https://openalex.org/keywords/positive-symptoms","display_name":"positive symptoms","score":0.9940000176429749},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":0.953000009059906},{"id":"https://openalex.org/keywords/dopamine-d2-receptor-antagonists","display_name":"dopamine D2 receptor antagonists","score":0.7820000052452087},{"id":"https://openalex.org/keywords/antipsychotic-efficacy","display_name":"antipsychotic efficacy","score":0.7839999794960022},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.5090000033378601},{"id":"https://openalex.org/keywords/chronic-schizophrenia","display_name":"chronic schizophrenia","score":0.6679999828338623},{"id":"https://openalex.org/keywords/positive-and-negative-syndrome-scale","display_name":"PANSS","score":0.5910000205039978}],"concepts":[{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.9661993384361267},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.8247655034065247},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.6919829845428467},{"id":"https://openalex.org/C123273963","wikidata":"https://www.wikidata.org/wiki/Q624758","display_name":"Psychopathology","level":2,"score":0.5971513986587524},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5923516154289246},{"id":"https://openalex.org/C2781353949","wikidata":"https://www.wikidata.org/wiki/Q3271533","display_name":"Dopamine antagonist","level":4,"score":0.5695239305496216},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5527167916297913},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.49280431866645813},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.432394802570343},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.42665329575538635},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41959360241889954},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4131212532520294},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40844473242759705},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36411577463150024},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.16287755966186523},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.10490536689758301},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006220","descriptor_name":"Haloperidol","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007555","descriptor_name":"Isoxazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007555","descriptor_name":"Isoxazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011985","descriptor_name":"Receptors, Serotonin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017448","descriptor_name":"Receptors, Dopamine D2","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:7520904","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7520904","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Clinical Trial"},{"id":"mag:46755809","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7520904","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2085145384","https://openalex.org/W2040538157","https://openalex.org/W2144513312","https://openalex.org/W48226018","https://openalex.org/W2418914422","https://openalex.org/W2018434135","https://openalex.org/W2006456852","https://openalex.org/W2146438680","https://openalex.org/W1670361954","https://openalex.org/W205922494"],"abstract_inverted_index":{"Dopaminergic":[0],"hyperactivity":[1],"mediated":[2],"via":[3],"D2":[4,18],"receptors":[5],"is":[6,104],"implicated":[7],"in":[8,37],"the":[9,65,79],"etiology":[10],"of":[11,14,28,31,62,68,89,113],"positive":[12,81,111],"symptoms":[13],"schizophrenia,":[15],"but":[16],"selective":[17],"antagonists":[19],"provide":[20],"imperfect":[21],"therapy.":[22],"This":[23],"article":[24],"describes":[25],"a":[26,29,33],"subanalysis":[27],"trial":[30],"risperidone,":[32],"combined":[34],"5-HT2A/D2":[35],"antagonist,":[36],"513":[38],"patients":[39,109],"with":[40,54,110],"DSM-III-R":[41],"chronic":[42],"schizophrenia.":[43,114],"Risperidone":[44],"at":[45],"2,":[46],"6,":[47],"10,":[48],"and":[49,56,64,82],"16":[50],"mg/day":[51],"was":[52],"compared":[53],"placebo":[55,73],"haloperidol":[57,69,97],"20":[58,98],"mg/day.":[59],"All":[60],"doses":[61],"risperidone":[63,90,103],"20-mg":[66],"dose":[67,88],"were":[70],"superior":[71],"to":[72],"(mean":[74],"change":[75],"from":[76],"baseline":[77],"on":[78],"PANSS":[80],"general":[83],"psychopathology":[84],"subscales).":[85],"The":[86],"6-mg":[87],"also":[91],"produced":[92],"significantly":[93],"more":[94],"improvement":[95],"than":[96],"mg.":[99],"We":[100],"conclude":[101],"that":[102],"an":[105],"effective":[106],"drug":[107],"for":[108],"features":[112]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}